Petrelintide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Petrelintide

Also known as: ZP-petrelintide, long-acting human amylin analogue, DACRA (dual amylin and calcitonin receptor agonist)

Long-acting amylin analogue / dual amylin and calcitonin receptor agonist (DACRA)

Research chemicalLast updated: October 19, 2026Based on 7 peer-reviewed studies

What it is

Petrelintide is an experimental weight-loss drug in clinical development for obesity, being studied as a potential standalone and combination therapy. It works by mimicking amylin, a hormone that signals fullness after eating, to reduce appetite and food intake. Not FDA-approved; Phase 2 trial data published in 2026; in active clinical development.

The scientific side

Petrelintide is a potent, stable, long-acting analogue of human amylin designed to be formulated at approximately neutral pH. It acts as a dual agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). As an amylin-based agent, its pharmacological class promotes satiation through central nervous system mechanisms, slows gastric emptying, and suppresses glucagon secretion — consistent with the class mechanism described for amylin analogues (PMID 42452898; PMID 42586227). Its mechanism of action is described as distinct from incretin-based treatments such as GLP-1 receptor agonists. Development involved optimization of chemical stability while retaining in vitro and in vivo potency.

Class: Long-acting amylin analogue / dual amylin and calcitonin receptor agonist (DACRA)

Administration & storage

Administration
Subcutaneous (SC) injection — self-administered once-weekly in phase 2 trial (PMID: 42810355)Subcutaneous (SC) injection — used in both SAD and MAD phase 1 trials (PMID: 42017294)Intravenous (IV) injection — 0.35 mg single dose in SAD phase 1 trial (PMID: 42017294)
Storage
No storage conditions for petrelintide are described in the reviewed abstracts.
Cautions
Nausea was the most common adverse event, occurring in 20% of petrelintide-treated participants vs 6% with placebo in the phase 2 trial, predominantly during dose escalation; it was largely mild.,Gastrointestinal adverse events (nausea, rare diarrhoea) were the most common TEAEs in phase 1 trials; one participant discontinued treatment due to GI TEAEs.,Vomiting was infrequent in the phase 2 trial (3% petrelintide vs 6% placebo) and was only experienced by the one participant who discontinued in phase 1 (PMID: 42810355; PMID: 42017294).,No serious or severe treatment-emergent adverse events were reported in phase 1 trials; no deaths were reported in the phase 2 trial (PMID: 42017294; PMID: 42810355).,Sterile technique should be maintained for any injectable compound; specific sterility guidance for petrelintide is not provided in the reviewed literature.,Petrelintide is still in clinical development; long-term safety data beyond 42 weeks are not yet available from the reviewed abstracts.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. Phase 2 trial (ZUPREME 1) completed March 2026; described as 'in clinical development'.

WADA

Not stated in reviewed literature — requires manual verification.

Health Canada

Not stated in reviewed literature — requires manual verification.